SCHOTT Pharma AG & Co. KGaA / DE000A3ENQ51

SCHOTT Pharma AG & Co. KGaA: Outlook for fiscal year 2026 and update of mid-term guidance

EQS-Ad-hoc: SCHOTT Pharma AG & Co. KGaA / Key word(s): Forecast/Change in Forecast
SCHOTT Pharma AG & Co. KGaA: Outlook for fiscal year 2026 and update of mid-term guidance

04-Dec-2025 / 18:53 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

---

SCHOTT Pharma: Outlook for fiscal year 2026 and update of mid-term guidance

Today, SCHOTT Pharma issues its financial guidance for fiscal year 2026: The company expects revenue growth at constant currencies in the range of 2-5% and an EBITDA margin of around 27%. This projection deviates from current market expectations (source: Vara consensus as of December 3, 2025) of 8.2% growth at constant currencies and an EBITDA margin of 28.8%.

Further, SCHOTT Pharma updates its mid-term outlook for 2027 to 2029 to a revenue CAGR of 6-8% and expects the EBITDA margin to improve over the coming years towards 30%.

Preliminary results for fiscal year 2025 are in line with market expectations and will be published in a press release later today. The full set of results for fiscal 2025 will be published on December 11, 2025, at 07:00 a.m. CET.

End of Inside Information

---

04-Dec-2025 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
View original content: EQS News

---

Language:	English
Company:	SCHOTT Pharma AG & Co. KGaA
	Hattenbergstraße 10
	55122 Mainz
	Germany
ISIN:	DE000A3ENQ51
WKN:	A3ENQ5
Indices:	SDAX
Listed:	Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange
EQS News ID:	2240736

End of Announcement	EQS News Service

---

2240736  04-Dec-2025 CET/CEST